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DOI 10.1186/s12879-015-0910-3RESEARCH ARTICLE Open AccessSevere morbidity after antiretroviral (ART)
initiation: active surveillance in HIV care
programs, the IeDEA West Africa collaboration
Yao Abo1,7*, Marcel Zannou Djimon4,6, Eugène Messou5,3, Eric Balestre2,3, Martial Kouakou5, Jocelyn Akakpo4,
Carin Ahouada4, Nathalie de Rekeneire2,3, François Dabis2,3, Charlotte Lewden2,3, Albert Minga1,7 and on behalf of
the IeDEA West Africa CollaborationAbstract
Background: The causes of severe morbidity in health facilities implementing Antiretroviral Treatment (ART) programmes
are poorly documented in sub-Saharan Africa. We aimed to describe severe morbidity among HIV-infected patients after
ART initiation, based on data from an active surveillance system established within a network of specialized care facilities
in West African cities.
Methods: Within the International epidemiological Database to Evaluate AIDS (IeDEA) - West Africa collaboration,
we conducted a prospective, multicenter data collection that involved two facilities in Abidjan, Côte d’Ivoire and
one in Cotonou, Benin. Among HIV-infected adults receiving ART, events were recorded using a standardized form.
A simple case-definition of severe morbidity (death, hospitalization, fever > 38°5C, Karnofsky index < 70%) was used
at any patient contact point. Then a physician confirmed and classified the event as WHO stage 3 or 4 according
to the WHO clinical classification or as degree 3 or 4 of the ANRS scale.
Results: From December 2009 to December 2011, 978 adults (71% women, median age 39 years) presented with
1449 severe events. The main diagnoses were: non-AIDS-defining infections (33%), AIDS-defining illnesses (33%),
suspected adverse drug reactions (7%), other illnesses (4%) and syndromic diagnoses (16%). The most common
specific diagnoses were: malaria (25%), pneumonia (13%) and tuberculosis (8%). The diagnoses were reported as
syndromic in one out of five events recorded during this study.
Conclusions: This study highlights the ongoing importance of conventional infectious diseases among severe
morbid events occurring in patients on ART in ambulatory HIV care facilities in West Africa. Meanwhile, additional
studies are needed due to the undiagnosed aspect of severe morbidity in substantial proportion.
Keywords: Antiretroviral therapy, Severe morbidity, Ambulatory HIV care facilities, West AfricaBackground
In December 2010, an estimated 5,640,000 Human
Immunodeficiency Virus (HIV)-infected people were re-
ceiving Antiretroviral Treatment (ART) in Sub-Saharan
Africa (SSA), which represented a 20% increase in ART
coverage compared to a year earlier [1]. Despite the rapid in-
crease in availability of antiretroviral drugs in SSA since* Correspondence: aysonabo@gmail.com
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unless otherwise stated.2004 [2], mortality and morbidity associated with HIV re-
main high among patients starting ART [3,4]. This high fre-
quency of Acquired Immuno Deficiency Syndrome (AIDS)-
related morbidity is due to late diagnosis of HIV infection
and consequently leading to a late initiation of treatment [5].
According to the available literature, severe morbidity is
common during the first months after ART initiation and
remains high thereafter. Specifically, this severe morbidity
is characterized by a high incidence of invasive bacterial
diseases and tuberculosis [6,7]. Among SSA hospitalized
HIV-positive patients, the most frequent causes of
hospitalization are AIDS-defining conditions, tuberculosisis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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morbidity was recorded among HIV-infected adults
followed up in routine conditions in SSA ambulatory care
centers [11,12]. In addition to these infectious diseases,
antiretroviral drugs expose patients to severe adverse
events [13-15]. With the increase of life expectancy as the
result of ART initiation, HIV-infected patients are more
likely to present with non infectious diseases [16].
Available data on morbidity mainly come from research
settings with advanced diagnostic capacities [3,4,7]. In
SSA, causes of severe morbidity and mortality after ART
initiation are poorly documented in health facilities imple-
menting ART under routine circumstances, as data collec-
tion is still a challenge in those settings [17].
To fill this lack of data, the International epidemiological
Database to Evaluate AIDS (IeDEA) was implemented in
the West African region. It was launched to collect and
harmonize data from multiple HIV⁄AIDS cohorts from in-
dustrialized and resource-limited countries. The IeDEA col-
laboration aims to address research questions in the field of
HIV⁄AIDS care and treatment, especially in low-income
countries, where most ART scale-up take place. The IeDEA
West Africa is a prospective and observational multi-
cohort collaboration established in 2006. It includes data
from 8 countries with 15 centers for adult-patients infected
with HIV on ART in Benin, Burkina Faso, Côte d’Ivoire,
Guinea-Bissau, Mali, Nigeria, Senegal and Togo [18,19].
This collaboration could help address questions that
have been poorly documented in this context, such as
morbidity. Because of rapid changes in therapeutic strat-
egies, a minimal morbidity surveillance in HIV care facil-
ities of SSA is required [20-22].
The objective of our study was, to describe severe
morbidity occurring among HIV-infected adult patients,
receiving ART based on surveillance data collected pro-
spectively under routine circumstances in HIV/AIDS
care facilities in SSA.Methods
Study design
The current study was conducted between December
2009 and December 2011, within the IeDEA network in
West Africa [17,18] (see Additional file 1). For the purpose
of this project, we conducted a prospective, multicenter
ancillary study that involved three health care facilities.
Among them, two were in Abidjan, Côte d’Ivoire: the
Medical Center for the Monitoring of Blood Donors
(CMSDS) and the Centre for Care, Research and Training
(Aconda-CePReF). The other one was in Cotonou, Benin:
the Outpatient Care Center of the National University
Hospital (CTA/CNHU). All these three facilities are am-
bulatory HIV care centers that participated on a voluntary
basis.Study population
The study population consisted of HIV-infected individ-
uals, aged 18 and over, receiving ART in one of the three
participating facilities. Those centers were chosen on the
basis of a convenience sampling among the ambulatory
care centers participating in the West Africa IeDEA
collaboration.
Definition of severe morbidity
We defined a severe event as the occurrence of one of the
following events: death, hospitalization, fever (temperature
above 385°C) or Karnofsky index < 70% in any patient on
ART. Any patient with at least one of these signs was in-
cluded in this study. The centers involved in this study
were exclusively outpatient clinics. Therefore, deaths were
reported by the patients’ siblings during telephone re-
minders made by the social workers. A standardized data
collection form was used to record these events.
Physicians and other Health care workers (HCWs) (data
collection technicians, social workers, nurses, pharmacy
aides) from participating centers were trained to identify
severe morbidity based on the four signs included in the
definition. HCWs other than physicians, initiate a form by
filling in the survey form with the sign(s) of severe mor-
bidity experienced by the patients and their identification
numbers. Physicians were responsible for completing the
forms with clinical examination results. In case the phys-
ician noticed signs of severe morbidity by himself, he
could initiate and fill the entire record.
Once the form was completed by the physician, add-
itional testing might be requested to confirm the diagno-
sis. The final diagnosis was established by the physician
in charge of the patient. This final diagnosis, either ac-
curate or syndromic was chosen for the study. First, the
diagnosis was accurate when it led to a specific disease
and was based on additional testing. Then, the diagnosis
was syndromic when it was mentioned as a sign and was
not based on further investigation. Each diagnosis was
classified by the physician according to the World
Health Organization (WHO) clinical stage classification
[23] and/or to the the Agence Nationale de Recherche
sur le Sida et les hépatites Virales (ANRS) [24].
A physician was appointed at each center for the
supervision of the study. He/she received all the forms
daily, checked data completeness and the accuracy.
Data collection
First, the physician in charge of the study at each center
controlled the quality of the filled out survey forms.
Next, documented severe events were subsequently
coded according to a validated list of codes of the Inter-
national Classification of Diseases, tenth revision (ICD-
10) [25]. Then, the coded events were entered into a
computer database and transferred from each health
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coordination center.
Main diagnostic procedures
Ambulatory care centers for HIV-infected patients need
to provide them with, both routine follow-up laboratory
examination and additional laboratory testing. The
Table 1 gives a summary of the available tests.
Description of study findings
For each severe event, we described the main diagnosis,
among the one, two or three diagnoses reported by the
physician. If a patient had several diagnoses, we deter-
mined one main diagnosis by using the following priority
order: first, WHO stage 4 opportunistic disease, second,
WHO stage 3 opportunistic disease, third, other infec-
tion, fourth, other cancer, Fifth, WHO stage 4 cachexia,
sixth, other disease and seventh, non specific event in-
cluding syndromic diagnosis and non specific WHO
stage 3 events (weight loss > 10%, chronic diarrhoea,
persistent fever). We also described the total number of
diagnoses and their percentage separately, using the total
number of events as denominator.
Statistical methods
Patient characteristics were described using the median
and interquartile range (IQR) of continuous variables
and the frequency distribution of categorical variables.
Ethical approval
The IeDEA West Africa Collaboration obtained
authorization from the Ethics committee “Comité de
Protection des Personnes Sud-Ouest et Outre-mer III”
in Bordeaux, France. Moreover, each site obtained
authorization from its National Ethics committee: TheTable 1 Main diagnostic procedures in the three participating
2011
Centers CMSDS
Diagnostic procedures
Monitoring routine tests
Full blood count *
CD4 lymphocytes *
Plasma urea and creatinine *
Glycemia *
Additional tests for diagnosis of diseases
Thick film *
Sputum examination ***
Radiography ***
Computed Tomography ***
*Available at the center and free of charge.
**Available on site but not free of charge.
***Not available at the center.“Comité National d’Ethique et de la Recherche (CNER)”,
in Côte d’Ivoire and the “Comité National d’Ethique
pour la Recherche en Santé (CNERS)”, in Benin. The
physicians in charge of patients at each site obtained
written informed consent from the patients included in
this study.
Results
Between December 2009 and December 2011, 978 HIV-
infected adults followed up in three facilities of the
IeDEA West Africa collaboration and presenting at least
with one severe event were included in this study. Pa-
tients were mainly female (71%), with a median age of
39 years (IQR: 33–45). The cumulative follow-up period
from ART initiation to the first severe event was 3465
person-years (PY) with a median of 23.1 months [IQR
(3.4 to 54.7)] (Table 2). Among the 978 patients, 570
(58.3%) were followed up at Aconda-CePReF, 210
(21.5%) at CTA/CNHU and 198 (20.2%) at CMSDS. In
these 978 patients, 1449 events occurred: 955 (65.9%) at
Aconda-CePReF, 255 (17.6%) at CTA/CNHU and 239
(16.5%) at CMSDS (Table 2).
The main diagnoses reported among these 1449 severe
events were: non-AIDS-defining infection (32.6%),
AIDS-defining illness (33.2%) with 23.3% in WHO stage
3 and 9.5% in WHO stage 4, suspected adverse drug re-
actions (7.1%), and finally non-infectious diseases and
non-AIDS-defining illnesses (4.8%). In 16% of the cases,
the diagnosis remained syndromic (Table 3). In this
group, anemia (32%), fever (20%) and digestive disorders
(13%) were the most common syndromic diagnoses. De-
tailed diagnoses reported for these severe events are pre-
sented in Table 4. Malaria (25%), pneumonia (13.4%)
and tuberculosis (7.7%) were the most common diagno-
ses. During the study period, 180 patients (13%) diedcenters, IeDEA West Africa, December 2009 to December
Aconda-CePReF CTA/CNHU
* *
* *
* *
* *
** ***
** ***
**: **:
** ***
Table 2 Characteristics at initiation of antiretroviral treatment (ART) and during follow-up (last visit) of HIV-infected
adults in the three participating centers, IeDEA West Africa, December 2009 to December 2011
Characteristics Total Aconda-CePReF CMSDS CTA/CNHU
N = 978 n = 570 n = 198 n = 210
At ART initiation
Sex, woman, n (%) 692 (71) 420 (74) 140 (71) 119 (57)
Age (years), median (IQR) 39 (33–45) 36 (31–44) 35 (31–41) 36 (31–42)
BMI (Kg/m2), median (IQR) 20.1 (17.9-22.7) 19.7 (17.6-22.2) 20.8 (18.7-23.7) 21.0 (18.8-24.6)
CD4 (/mm3), number, median (IQR) 137 (59–239) 136 (61–249) 157 (60–242) 108 (47–180)
Antiretroviral treatment, n (%)
2NRTIs + 1NNRTIs 678 (69.3) 381 (66.8) 135 (68,2) 162 (77,1)
2NRTIs + 1PI 87 (9) 48 (8) 26 (13) 13 (6)
Other 213 (22) 141 (25) 37 (19) 35 (17)
Follow-up data*
Total follow-up (months), median (IQR) 34.9 (16.3-67.1) 35.5 (14.6-66.2) 35.0 (18.2-54.1) 33.5 (16.9-76.6)
Follow-up until event (months), median (IQR) ((I(((IQR) 23.1 (3.4-54.6) 24.6 (2.6-55.5) 18.7 (3.5-43.1) 23.2 (5.8-66.2)
CD4 cell/mm3 median (IQR) 269 (103–467) 267 (102–453) 289 (124–517) 237 (73–468)
WHO stage, n (%)
Stage 1 or 2 167 (17.1) 29 (5) 119 (60.2) 19 (9)
Stage 3 242 (24.7) 128 (22) 48 (24.2) 66 (31)
Stage 4 80 (8.2) 41 (7) 27 (13.6) 12 (6)
IQR = Interquartile Range.
BMI = Body Mass Index.
WHO =World Health Organisation.
ART = Antiretroviral Treatment.
Aconda-CePReF = Centre for Care, Research and Training.
CMSDS =Medical Centre for Monitoring Blood Donors.
CTA/CNHU = Outpatient Treatment Centre of the National University Hospital.
NNRTIs = Non Nucleoside Reverse Transcriptase Inhibitors.
PIs = Protease Inhibitors.
AZT = Zidovudine.
D4T = Stavudine.
3TC = Lamivudine.
*: close to the event: At the time of the morbid event.
Table 3 Main* diagnoses of the 1449 events reported in HIV-infected adults receiving antiretroviral treatment, IeDEA
West Africa, December 2009 to December 2011
Diagnosis classification,
number (%)
Total 1449 Aconda-CePReF CMSDS CTA/CNHU
N = 1449 n = 955 n = 239 n = 255
AIDS-defining events
WHO stage 4 events 137 (9.5) 68 (7.1) 31 (13) 38 (14.9)
WHO stage 3 events 338 (23.3) 214 (22.4) 24 (10) 100 (39.2)
WHO stage 2 events 6 (0.4) 5 (0.5) 0 (0) 1 (0,4)
Non-AIDS-defining events
Non AIDS classifying infections 472 (32.6) 379 (39.7) 51 (21.3) 42 (16.5)
Side effects** 104 (7.2) 34 (3.6) 32 (13.4) 38 (14.9)
Other diagnosed diseases 63 (4.3) 35 (3.7) 12 (5) 16 (6.3)
Syndromic diagnoses*** 228 (16.0) 160 (17.0) 55 (23.0) 13 (5.1))
Death 101 (7.0) 60 (6.0) 34 (14.2) 7 (3.0)
*: one diagnosis per event.
**: (anemia = 36, peripheral neuropathy = 33, toxiderma = 21, neutropenia = 5, lipodystrophy = 4, acute delusional psychosis = 2, hyperlactatemia = 2, hepatitis = 1).
***[anemia = 72, fever = 46, general signs (Asthenia, anorexia = 37), digestive signs (diarrhea, vomiting) = 30, other signs = 43].
Abo et al. BMC Infectious Diseases  (2015) 15:176 Page 4 of 8
Table 4 Syndromic and definitive diagnosesγ according to WHO stages and ANRS degrees of severity, in HIV-infected
adults receiving antiretroviral treatment, IeDEA West Africa, December 2009 to December 2011
Diagnoses, number Total WHO classification ANRS degrees of severity Hospitalisation* Death**
N = 1675 (%) Stage 3 Stage 4 Degree 3 Degree 4
Infectious events
Parasitic events
Malaria 359 (24.8) 99 12 127
Cerebral toxoplasmosis 24 (1.7) 0 24 15 3
Other parasitic events‡ 9 (0.6) 3 1 2
Bacterial events
Pneumonia 194 (13.4) 194 79 2
Tuberculosis 111 (7.7) 45 66 43 4
ENT infection 26 (1.8) 2 3
Severe bacterial infection 17 (1.2) 17 7 1
Other eventsβ 12 (0.8) 2 2 3
Mycotic events
Oral candidiasis 138 (9.5) 133 8
Other mycoses£ 25 (1.7) 11 1
Infectious diarrhoea 121 (8.4) 45 12 75
Skin infections 16 (1.1) 1 5
Viral infectionsπ 35 (2.4) 25 1 15 1
Other infectious eventsα 27 (1,9) 5 4 10
Non infectious diagnosis
Peripheral neuropathy*** 52 (3.6) 39 5 5
Toxiderma 19 (1.3) 6 7 11
Tumors 17 (1.2) 11 1 9
Other non infectious diagnosesΨ 46 (3.2) 8 17 13 1
Non specific events
Anemia† 164 (11.3) 57 82 84 3
Fever 49 (3.4) 4 9 4 10 1
Diarrhoea 25 (1.7) 5 11 1 18 2
Other general signsθ 57 (3.9) 23 16 41 2
Other non specificф 31 (2.1) 7 5 32 3
Death 101
ENT = Ear Nose Throat.
γ Several diagnoses for a same event.
*Number of events with at least one day in day care.
** Number of death occurring after the event.
*** including 37 neuropathies secondary to ART initiation.
(%) Percentage calculated based on the number of events.
†including 54 anaemia secondary to a treatment.
‡6 ameibiasis, 2 pneumocystoses, 1 microsporidia.
β9 urinary infections, 2 appendicites, 1 cholecystitis.
£11 vaginal candidosis, 10 oesophagal candidosis, 3 digestive candidosis, 1 cryptococcal.
π21 HIV-related cachexia syndrome, 8 herpes zoster, 4 HIV-related encephalopathies, 2 herpes.
Tumors: 9 kaposi, 4 benign tumors, 2 unkown evolutive tumors, 1 cervical cancer, 1 Non-Hodgkin malignant Lymphoma.
Ψ Cardio-vascular (6 arterial hypertension, 4 peripheral veins, 2 stroke), Renal (6 nephropathy, 6 renal failure), metabolic (5 abnormal fat distribution, 1 lactic
acidosis, 1 diabetes), Genito-obstetric (two abortions, two other), Gastrointestinal (3 gastric or duodenal ulcers, 1 chronic pancreatitis, 7 other.
α7 genital infections, 6 osteoarticular infections, 6 broncho-pneumopathy, 5 meningitis, 2 stomatitis, 1 hepatitis.
θ19 asthenia, 21 dehydration, 17 under-nutrition.
Ф1 digestive disorders, 6 hemiplegia/tetraplegia, 6 psychiatric signs, 5 neutropenia, 2 liver signs, 11 other signs.
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determined with precision (Table 4). The distribution of the
1449 severe events according to the circumstances of their
identification was: regular or day hospitalization (41.5%),
fever (29.8%), death (8.6%), Karnofsky index < 70% (4.5%),
other reasons (16%).
Discussion
A prospective data collection system for severe morbid-
ity was performed in three ambulatory HIV care facilities
in West Africa. We collected standardized data from
several patient contact points in each facility. Non-
AIDS-defining infectious diseases and AIDS-defining
diseases were the most frequent groups of morbid events
observed in one-third of the patients. The most common
specific diagnoses were malaria, pneumonia and tuber-
culosis. The diagnosis was defined as syndromic in one
out of five cases.
This study showed the feasibility of routine collection
of severe morbidity data among patients on ART based
on: (i) the definition of reported signs of severe morbid-
ity adapted to all staff and all care facilities and (ii) the
definition and use of a simple data form. This
organization involving all staff (data collection techni-
cians, social workers, paramedics and physicians) and all
services (reception desk, pharmacy, nursing, medical
consultation, day care) had the advantage of being re-
producible and affordable due to its integration within
the existing system.
Regarding the WHO clinical stage 3 or 4 events, our
results are consistent with those of previous studies [3,4]
and could be explained by the late diagnosis of HIV in-
fection or delayed ART initiation in this resource-
limited setting [21]. Despite recent and repeated changes
in the criteria for ART initiation in resource-limited
countries [20,21,26], these changes were far from being
fully implemented at the time of the study in most of
these countries. Previous studies conducted in the con-
text of the 2006 WHO criteria for ART initiation, have
shown that patients started ART late with low CD4 [27].
This delay in ART initiation could explain the persist-
ence of AIDS-defining illnesses after ART initiation. En-
hanced and multiple opportunities of HIV testing are
necessary to change this pattern of events.
The World Health Organization recently recommended
to supply centers with rapid diagnostic tests for malaria
[28]. This decision was not implemented in the participat-
ing centers during the study period. Indeed, among the
three participating centers, only the CMSDS performed
routine thick smears in suspected malaria cases at no cost
to patients. Despite the high endemicity of malaria in the
study area and the consistency of our results with those of
some authors [29], we discussed the hypothesis of a pos-
sible overestimation of this diagnosis as confirmed byother studies [30,31]. Indeed one of the signs of serious ill-
ness was fever which is also one of the main signs of mal-
aria. Some patients were not able to benefit from this
testing due to financial constraints. Some of them could
have been wrongly classified as malaria cases, thus over-
estimating the number of cases.
We also found that pneumonia as well as tuberculosis
were the most common frequent AIDS-defining event
while on ART. This result was also mentioned in previ-
ous studies in SSA [32,33], confirming the endemicity of
these lung diseases in the study area at the current level
of ART coverage [34,35].
Improvements have been made in the health care sys-
tem in Africa more particularly in SSA. However, pro-
gress remains to be made. Among the challenges health
care services deal with in Africa, underdeveloped infra-
structures and weak healthcare systems are the most
predominant [36]. As regards to HIV management, over
75% of expenses related to HIV care are faced by pa-
tients, and more than 50% of these expenses are allo-
cated to the diagnosis and treatment of opportunistic
infections) [37-39]. One of the consequences of these
weaknesses is the difficulty to investigate the diagnoses
of morbid events observed in patients. Therefore, we
recommend strengthening the capacity of laboratories in
HIV care facilities, by providing them with general labora-
tory testing in addition to efforts made to have antiretroviral
drugs and specific HIV tests available in outpatient centers.
Some of the events in this study were reported as syn-
dromic diagnoses. Given the seriousness of some of these
signs (fever, diarrhea), providing outpatient facilities with
rapid diagnostic tests for malaria or conventional X-rays,
should elucidate some of the diagnoses. Indeed, these gen-
eral laboratory tests are part of the essential components of
a basic package of HIV care and treatment [40,41]. Free ac-
cess to those general laboratory testing in addition to the
current free access to ART and specific HIV testing [42,43]
will improve their accessibility.
The main strengths of this study are its prospective and
multicenter design. First, a prospective study because for
each patient’s symptom, all the information were docu-
mented according to a standardized procedure that mini-
mized the risk of information bias. Then, a multicenter
study, as it involved a large and unselected population of
HIV-infected patients in care in the West African region.
The use of a standardized data collection form contributed
to ensure accuracy in data collection and limitation of var-
iations within and among facilities. The involvement of al-
most all health care professionals at all levels and from all
services was also instrumental in collecting the maximum
number of events occurring during the study period.
Our study also had some limitations. The severity of a
morbid event can be a reason for treatment discontinu-
ation in HIV care centers. Thus, the methodology of our
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patients with severe morbidities at the three study facil-
ities, is a limitation. Some patients suffering from severe
events with restricted mobility and those with severe
events lacking financial resources to travel to the facilities
may have been excluded from this study, therefore leading
to a selection bias. Another limitation is that specific signs
of interest were identified a priori before taking the event
into account. Some events may have been severe but with-
out any of these predefined signs, thus leading to their in-
appropriate exclusion. In addition, due to the lack of
resources, some patients might have restricted access to
definitive diagnoses. Besides, some hospitalizations might
have not been reported to us. All these biases may have
contributed to an underestimation of severe morbidity.
In order to carry out an efficient intervention and de-
liver a more adequate service in a context of general
weak health systems, further studies with access to diag-
nostic tests are needed to confirm the patterns observed
in terms of syndromic diagnoses. Such studies could
contribute to promote funding and the routine use of
general laboratory tests to diagnose morbid events in
resource-limited settings.
Conclusion
Standardized and routine collection of severe morbidity
data is possible in HIV/AIDS care facilities under rou-
tine circumstances. This study highlights the ongoing
importance of common infectious diseases among severe
morbid events occurring in patients on ART in national
HIV care facilities in West Africa. Meanwhile, additional
studies are needed due to the undiagnosed aspect of se-
vere morbidity in substantial proportion.
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